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ABSTRACT  32 
Retinal pigment epithelium (RPE) cell integrity is critical to the maintenance of retinal function. 33 
Many retinopathies such as age-related macular degeneration (AMD) are caused by the 34 
degeneration or malfunction of the RPE cell layer. Replacement of diseased RPE with healthy, stem 35 
cell derived RPE is a potential therapeutic strategy for treating AMD. Human embryonic stem cells 36 
(hESC) differentiated into RPE progeny have potential to provide an unlimited supply of cells for 37 
transplantation but challenges around scalability and efficiency of the differentiation process still 38 
remain. Using hESC-derived RPE as a cellular model, we sought to understand mechanisms that 39 
could be modulated to increase RPE yield following differentiation. We show that RPE 40 
epithelialization is a density-dependent process and cells seeded at low density fail to epithelialize. 41 
We demonstrate that activation of the cAMP pathway increases proliferation of dissociated RPE in 42 
culture, in part through inhibition of TGFβ signalling. This in turn results in enhanced uptake of 43 
epithelial identity even in cultures seeded at low density. In line with these findings, targeted 44 
manipulation of the TGFβ pathway with small molecules produces an increase in efficiency of RPE re-45 
epithelialization. Taken together, these data highlight mechanisms that promote epithelial fate 46 
acquisition in stem cell derived RPE. Modulation of these pathways has potential to favorably impact 47 
upon scalability and clinical translation of hESC-derived RPE as a cell therapy. 48 
 49 
INTRODUCTION 50 
Retinal pigment epithelium cells are a highly specialised, polarised cell type situated as a tightly 51 
packed monolayer between photoreceptors and the choroid. RPE cells help to maintain homeostasis 52 
and photoreceptor function in the retina via a range of processes including metabolism and storage 53 
of retinoid, phagocytosis of rod outer segments, scattered light absorption, barrier activity and ion 54 
transport [1]. Loss of RPE function is associated with diseases such as Age-Related Macular 55 
Degeneration (AMD), Retinitis Pigmentosa, proliferative vitreoretinopathy (PVR) and diabetic 56 
retinopathies among others, which often result in loss of vision [2]. The prevalence of AMD is on the 57 
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rise with increasing population longevity [3], which necessitates the development of new 58 
therapeutic approaches to treat this disease. A potential treatment for at least some of these ocular 59 
pathologies is the replacement of the dysfunctional RPE with healthy RPE including RPE derived from 60 
pluripotent stem cells [4]. Several studies have demonstrated successful derivation of mature RPE 61 
from human embryonic stem cells (hESC) or human induced pluripotent stem cells (hiPSC) using a 62 
range of differentiation protocols which produce RPE at varying levels of efficiency and time scales 63 
[5-7]. Stem cell derived RPE are functional [8-10] and have a gene expression signature equivalent to 64 
primary RPE [11-13]. Furthermore, their transplantation shows long-term protective effects leading 65 
to restored visual function in animal models of retinal dystrophy [14-17]. However, manufacture of 66 
transplantation-ready RPE cells with high yield and purity under conditions compatible with good 67 
manufacturing practices (GMP) still remains a significant challenge that needs to be overcome in 68 
order to successfully use this approach more widely. 69 
RPE cells are normally quiescent in the adult eye. However, in vitro dissociation and passaging 70 
procedures release RPE from cell cycle arrest and induce proliferation. This is accompanied by an 71 
epithelial-mesenchymal transition (EMT) where cells deviate from an epithelial state and acquire a 72 
mesenchymal phenotype. This is followed by a FOXM1 dependent mesenchymal-epithelial transition 73 
(MET) that results in re-uptake of epithelial characteristics [18]. The proliferative capacity of RPE 74 
allows serial expansion of cells in culture, albeit limited to a few passages, as cells lose key 75 
cytological and functional attributes with extended passage [19]. This limits the capacity of 76 
expansion of RPE with respect to manufacturing cells at scale for therapy. In this report, we sought 77 
to further understand the molecular mechanisms underpinning the acquisition of RPE cell fate and 78 
investigate the contribution of cellular proliferation together with cellular density to this process. 79 
Manipulation of these mechanisms would potentially allow better control of the differentiation and 80 
expansion process which might favourably impact cell production for clinical applications.  81 
Cyclic AMP (cAMP) is a second messenger used in intracellular signal transduction and can regulate 82 
the function of protein kinases which in turn phosphorylate other proteins including transcription 83 
Page 4 of 132
5 
 
factors such as CREB. Activation of cAMP-inducible genes regulate cellular processes such as 84 
differentiation and proliferation in a variety of cell types [20]. In RPE cells, cAMP has been shown to 85 
promote differentiation and maturation purportedly via proliferation-independent mechanisms such 86 
as promoting melanosome and pigmentation related pathways [21-24]. Approaches to increase 87 
cAMP e.g with the use of Vasointestinal Peptide, a hormone that raises intracellular cAMP, have 88 
been utilized in directing differentiation of embryonic stem cells towards the RPE lineage [9]. 89 
Similarly, review of the literature suggests that cAMP signalling controls migratory and fibrotic 90 
responses similar to those seen in PVR [25-27]. Therefore, we sought to determine whether cAMP 91 
treatment impacted gain of RPE identity during in vitro dissociation and culture of hESC-derived RPE. 92 
Interestingly, we observed that treatment with dibutyryl-cAMP (dbcAMP, Bucladesine), a cell 93 
permeable synthetic analogue of cAMP or use of molecules such as forskolin that increase 94 
intracellular cAMP through activation of Adenylyl cyclase, promote re-acquisition of RPE fate across 95 
a range of seeding densities in a proliferation dependent manner. Investigation into the underlying 96 
molecular pathways further suggested that interplay between cAMP signalling and the TGFβ 97 
pathway might be responsible for the phenotypic effects observed. 98 
The TGFβ pathway plays a central role in several cellular processes where it transduces extracellular 99 
signals into intracellular transcriptional responses that control cell growth, apoptosis, and 100 
differentiation. The TGFβ superfamily of endogenous signaling ligands consists of more than 25 101 
different ligands including BMPs, growth and differentiation factors and activins. TGFβ ligands 102 
(TGFβ1, β2 and β3) recruit TGFβ type II receptors (TGFβR2, ACTRIIA, or ACTRIIB) with a set of type I 103 
receptors (ALK4, ALK5, or ALK7). Receptor dimerization together with phosphorylation of  SMADs 104 
2/3 due to the receptor serine/threonine kinase activity leads to  SMAD nuclear translocation and 105 
downstream regulation of transcription resulting in signal propagation [28]. In this report, we show 106 
that inhibition of TGFβ signalling, in particular through inhibition of ALK5 kinase activity, with the use 107 
of small molecule tools results in an increase in epithelial phenotype of RPE. This suggests that 108 
signaling through TGFβ type I receptors, is an important determinant of epithelial cell fate.  109 
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In summary, this study furthers our understanding of the biology of stem cell derived RPE and 110 
additionally highlights potential points of intervention in pathways that could be targeted to 111 
increase efficiency of generating RPE suitable for transplantation.   112 
 113 
MATERIALS AND METHODS 114 
1. Cell culture and manipulations: RPE were generated from the hESC line SHEF1 (obtained from 115 
Axordia Ltd, also available in the UK Stem Cell Bank with the accession number R-05-007) using the 116 
spontaneous differentiation method described previously [7]. Pluripotent cells were cultured as 117 
feeder-free colonies on hESC-qualified Matrigel (BD Biosciences) using mTesR1 media (StemCell 118 
Technologies). RPE foci (Passage 0, P0) were excised with a scalpel and dissociated into a single cell 119 
suspension using Accutase (Gibco) and plated onto CellStart (Invitrogen) coated surfaces for 120 
expansion for a period of 8 weeks. For all experiments, the starting population of cells used were at 121 
P1 or P2 such that each round of expansion led to 3-4 population doublings. For experiments 122 
involving culture of cells in transwells, cells at P1 were plated on Vitronectin (AMS Bio) coated 123 
transwells at a density of 362500 cells/cm
2
 and cultured for a period of 3 weeks. Quantification of 124 
VEGF and PEDF in the cell culture supernatant was performed on the Mesoscale discovery platform 125 
using commercially available kits (MS6000, Human VEGF PEDF duplex assay). Bead phagocytosis 126 
assay was performed using FluoSpheres polystyrene microspheres (1.0μm Red; Invitrogen) following 127 
a published protocol [29]. Where required, media was supplemented with 10μM Forskolin (Sigma), 128 
0.5mM dbcAMP (Sigma), 10ng/ml TGFβ1 or 10μg/ml 1D11 (R&D Biosystems) at the time of seeding. 129 
For screening, compounds were obtained from the Pfizer library, solubilized in 100% DMSO and 130 
serially diluted such that final assay and vehicle concentration was 0.1% DMSO. ALK2 inhibitors 131 
DMH1 and LDN-212854 were purchased from Tocris. For all treatments, media was replenished 132 
three times per week.  133 
2. RNA extraction, cDNA synthesis and quantitative PCR: Total RNA was extracted from RPE cells 134 
using the RNEasy Mini or Micro Kit (Qiagen) with on-column DNase digestion. cDNA was synthesized 135 
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using the High Capacity cDNA Synthesis kit (Applied Biosystems). Individual gene expression was 136 
assessed using predesigned Taqman assays and the reactions were carried out on the ABI7900 or 137 
CFX96 platform. Gene expression in all instances was quantified by the Relative quantification 138 
method of 2
-ΔΔCt  
 and normalized to geometric means of housekeeping genes. 139 
3. Microarray analysis: mRNA was hybridized on Illumina HT-12v4 BeadChips according to 140 
manufacturer’s instructions. Raw microarray data was log transformed and quantile normalised 141 
using the beadarray package in Bioconductor. Differential expression analysis was performed using 142 
limma and geneset enrichment analysis with camera. All other analysis was performed with standard 143 
Bioconductor/R packages. Standard hierarchical clustering algorithms were used to achieve visual 144 
clarity of the heatmaps. The microarray data are available in the ArrayExpress database under 145 
accessions E-MTAB-854 and E-MTAB-3878. 146 
4. Immunocytochemistry: Samples were fixed in 4% paraformaldehyde in PBS for 15 min followed by 147 
blocking and permeabilization using 0.3% Triton X-100 in PBS and 10% normal donkey serum. 148 
Primary antibodies used in this study are:  mouse anti-PMEL17 (1:25, Dako M0634), rabbit anti-Ki67 149 
(1:500, VectorLabs VP-K451), rabbit anti-ZO1 (1:100, Zymed 187430), mouse anti-αSMA (1:1000, 150 
Sigma A5228), mouse anti-CRALBP (1:200, Affinity Biosciences MA1-813), rabbit anti-MERTK (1:50, 151 
Abcam ab52968). For EdU incorporation, cells were treated with 10µM EdU 18 hours prior to 152 
fixation. EdU incorporation was measured using the Click-iT 488 Imaging kit (Life Technologies) 153 
according to manufacturer’s instructions. Nuclei were counterstained with the nuclear dye 4',6-154 
diamidino-2-phenylindole (DAPI). For immunocytochemistry of transwell sections, the transwell 155 
membrane was fixed and frozen in a cryomold containing M1 embedding matrix and 10μm sections 156 
were prepared using a cryostat and immunostained. Images were captured and analyzed on the 157 
ImageXpress platform (Molecular devices) or on a confocal microscope (Leica).  158 
 159 
RESULTS 160 
1. RPE epithelialization is a density-dependent process.  161 
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Although RPE are differentiated epithelial cells, they retain the ability to change state into a 162 
mesenchymal phenotype when dissociated and cultured. This transitional state then undergoes a 163 
mesenchymal-epithelial transition to re-differentiate into an epithelial phenotype (Figure 1A) [18]. 164 
Successful epithelialization is critically reliant on seeding density such that cells seeded at high 165 
density successfully re-epithelialize whereas cells seeded at low density remain mesenchymal. In 166 
order to gain further insight into this density dependent process, we used whole genome 167 
microarrays to analyse a transcriptional profile time course of cells seeded either at high (100000 168 
cells/cm
2
) or low (8000 cells/cm
2
) density. Strikingly, the expression patterns of most genes clustered 169 
into two distinct, symmetrical groups (Figure 1B).  Genes in the first cluster exhibit relatively high 170 
expression in the starting RPE sample (D0), but show an immediate drop in expression following 171 
dissociation. These genes then steadily increase in expression towards the starting level in the high 172 
density culture but remain suppressed in the low density cultures. The second cluster shows the 173 
opposite pattern: initially low in expression, these genes immediately rise following dissociation 174 
before decreasing to their D0 level in the high density culture, whereas their expression tends to 175 
remain high in the low density cultures. Importantly, we note that the transcriptional state of the 176 
cells seeded at high density returns towards that of the starting RPE population, whereas cells 177 
seeded at low density remain distinct. The list of genes belonging to clusters 1 and 2 can be seen in 178 
Supplementary Table 1. 179 
We further examined the expression of epithelial and mesenchymal markers and, consistent with 180 
visual observations, there was an initial upregulation of mesenchymal markers concomitant with a 181 
decrease in epithelial and RPE specific markers upon dissociation. This was followed by a re-182 
expression of epithelial markers in high density cultures with time indicating a successful 183 
mesenchymal-epithelial transition. In contrast, cells seeded at low density retained high expression 184 
of mesenchymal markers and low expression of epithelial markers throughout the timecourse 185 
(Figure 1C). Immunostaining for representative RPE markers PMEL17, RLBP1 and ZO1 and the 186 
mesenchymal marker α-SMA was consistent with the mRNA expression pattern confirming that low 187 
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density cultures did not display an epithelial phenotype (Figure 1D). Taken together, this analysis 188 
strongly suggests that an appropriately high seeding density is required for successful 189 
epithelialization. In addition, we confirmed that the RPE obtained following re-epithelialization were 190 
polarized and functional in terms of phagocytosis and ability to secrete trophic factors such as VEGF 191 
and PEDF, which are key features of native RPE.  RPE were seeded on transwell inserts and cultured 192 
for a period of 3 weeks. Cross-sections of the insert were immunostained for the RPE markers ZO1, 193 
MERTK and PMEL17 (Supplementary figure 1A). The expression of ZO1 was restricted to the cell 194 
junctions, MERTK to the apical surface and PMEL17 throughout the cell body consistent with cell 195 
polarization. Furthermore, RPE were capable of phagocytosing fluorescently labelled beads 196 
(Supplementary figure 1B) which serves as a surrogate measure of ability to phagocytose rod outer 197 
segments [30]. Finally, we measured the ability of RPE to secrete VEGF and PEDF. Spent media was 198 
collected from RPE cultured on transwells and compared to ARPE19 cells cultured under identical 199 
conditions. We observed an increase in VEGF and PEDF secretion by RPE with time in culture (e.g at 200 
day 21 vs. day 4) indicative of attainment of polarisation and functionality upon re-epithelialization 201 
(Supplementary figure 1C). In contrast, ARPE19 did not secrete detectable levels of PEDF consistent 202 
with the notion that they do not replicate all aspects of native RPE function.  203 
 204 
2. Increasing cAMP levels promotes acquisition of RPE identity in a time- and density- dependent 205 
manner 206 
We have shown a density-dependent effect on re-acquisition of epithelial identity where cells 207 
seeded at high density readily differentiate back into a RPE state over a period of time but cells 208 
seeded at a lower density do not. Next, we wanted to understand the pathways underlying RPE 209 
epithelialization and identify their putative modulators. Given the literature suggesting effects of 210 
cAMP signalling on RPE characteriscs [21-25], we selected forskolin (FSK) as a tool to increase 211 
intracellular cAMP levels. We found that treatment with 10μM FSK led to a consistent increase in 212 
pigmentation and epithelial characteristics across a range of seeding densities (Figure 2A, 213 
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Supplementary figure 2). This prompted us to ask whether FSK treatment modulated the gene 214 
expression profile of cells during the time course of RPE culture. Taqman low density arrays (TLDA) 215 
were used to perform qPCR with a panel of 24 genes indicative of epithelial or mesenchymal identity 216 
(Supplementary figure 3). We performed a principal component analysis on this multivariate data 217 
and found that the first principal component correlated with high expression of epithelial genes and 218 
low expression of mesenchymal genes. We used the first principal component as a univariate 219 
weighted score of RPE identity and therefore used it to measure the effect of FSK at a range of 220 
seeding densities (2.5k, 10k, 15k, 20k, 25k, 27.5k, 30k, 38k; k=x1000cells/cm
2
) after 63 days in 221 
culture. This showed that treatment with FSK led to an increase in ‘RPE-score’ i.e acquisition of the 222 
RPE phenotype, at every plating density tested (Figure 2B). 223 
A limitation of the TLDA-based approach is the comparatively limited set of genes profiled. Due to 224 
this, we were limited in our ability to generate unbiased hypotheses about the underlying 225 
mechanism of increased epithelialization with increased cAMP levels. We therefore sought to extend 226 
these initial qPCR-based observations to global gene expression profiling. In order to generate a 227 
comprehensive dataset, we used microarrays to assess the effect of increased cAMP signalling on 228 
cells seeded at 10000, 20000 and 40000 cells/cm
2
 over time (3, 15 and 34 days in culture). The 229 
stable, cell permeant cAMP analogue, dbcAMP, was used to enhance intracellular cAMP signalling in 230 
this study. Interestingly, principal component analysis showed that at every timepoint sampled, the 231 
gene expression signature of cells treated with 0.5mM dbcAMP was equivalent to cells seeded at 232 
double the density in media alone (Figure 3A).  For example, the expression profile of cells seeded at 233 
10000 cells/cm
2
 with dbcAMP was equivalent to that of cells at 20000 cells/cm
2
 without dbcAMP. 234 
Similarly, the expression profile of cAMP-treated cells at 20000 cells/cm
2
 was comparable to cells at 235 
40000 cells/cm
2
 without supplementation. A clustered heatmap representation of the top 1% 236 
variable genes reiterates the same observation of a ‘doubling effect’ of density in cells exposed to 237 
dbcAMP where cells treated with dbcAMP clustered with cells seeded at twice the density without 238 
dbcAMP exposure (Figure 3B). We next looked at the expression of specific RPE markers and found 239 
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them to be consistent with the profiles seen with the whole genome analyses (Figure 3C). These 240 
expression patterns were further confirmed by gene specific qPCR for representative genes 241 
(Supplementary figure 4A) together with immunostaining for protein expression (Supplementary 242 
figure 4B). Additionally, we determined that a dose of at least 0.5mM dbcAMP was required to see 243 
this effect (Supplementary fig 4C). In summary, these data show that intracellular elevation of cAMP 244 
signalling leads to an increase in acquisition of RPE phenotype. 245 
 246 
3. Increasing cAMP levels promotes RPE proliferation 247 
In order to gain insight into the molecular mechanisms by which cAMP positively modulates RPE 248 
fate, we performed geneset enrichment analyses (GSEA) of the dbcAMP induced expression 249 
changes. Besides markers of the RPE phenotype, there was enhanced representation of sets of 250 
genes associated with increased proliferation (Figure 4A, Supplementary table 2). This suggested 251 
that the increased epithelial phenotype could occur as a result of increased proliferation. In order to 252 
test this hypothesis, we assessed proliferation in cells treated with or without dbcAMP, using the 253 
incorporation of EdU, a modified thymidine analogue, which can be visualized using ‘Click’ chemistry 254 
dependent imaging [31]. We found an increase in proliferating cells upon supplementation with 255 
dbcAMP on days 7, 14 and 21 of culture (Figure 4B). Importantly, with increased time e.g at day 56, 256 
there was no significant difference in proliferation between cells supplemented with dbcAMP or not 257 
(Figure 4B). This suggests that although intracellular cAMP elevation promotes proliferation, it is not 258 
an uncontrolled feature and homeostatic RPE mechanisms are in play to achieve quiescence after 259 
the initial phase of proliferation upregulation. An increase in proliferation, measured by 260 
immunostaining for Ki67, was seen upon treatment of cells with FSK (Figure 4C) showing that 261 
intracellular cAMP elevation by different methods resulted in a similar effect. We also determined 262 
the optimum period of dbcAMP exposure required to observe effects on proliferation. Cells were 263 
seeded at a density of 38000 cells/cm
2
 and cultured for a period of 8 weeks with continuous dbcAMP 264 
treatment for either 2 weeks, 3 weeks or the entire duration of 8 weeks. The increase in 265 
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proliferation resulted in an increased number of cells whose nuclei stained positive for the nuclear 266 
specific fluorescent dye DAPI. Using DAPI count as a surrogate for cell number estimation, we 267 
observed no difference in cell number between the dbcAMP exposure times tested (Figure 4D). 268 
From this data, we conclude that exposure of cells to dbcAMP for the first 2 weeks post dissociation 269 
and seeding is sufficient to result in increased proliferation.  270 
 271 
4. Activation of cAMP signalling suppresses the TGFβ pathway to promote successful 272 
epithelialization 273 
To understand mode of cAMP action, causal reasoning analysis [32] of the gene expression dataset 274 
was performed to predict molecular regulators of the observed gene expression changes. We 275 
compared the gene expression profiles of cultures seeded at 20000 cells/cm
2
 in the presence or 276 
absence of dbcAMP at day 34 and observed that TGFβ signalling was a key mechanism being 277 
supressed by dbcAMP treatment (p = 7.95x10
-17
). In order to further decipher the interplay between 278 
cAMP-TGFβ pathways, we made use of information available in the literature. It is known that 279 
activation of the TGFβ pathway leads to downstream activation of SMADs 2/3 which then directly 280 
affect gene expression by binding to gene promoters. We identified genes that are directly bound by 281 
SMAD3 using a publically available ChIP-Seq dataset [33]. We then investigated how the expression 282 
of these genes changed upon dbcAMP treatment. Interestingly, we observed a significantly 283 
decreased expression of SMAD3 responsive genes in RPE cells treated with dbcAMP (p < 1x10
-10
) 284 
(Figure 5A). Taken together, these two lines of evidence support the notion that active cAMP 285 
signalling, which promotes proliferation and epithelialization, is associated with inhibition of the 286 
TGFβ pathway in RPE.  287 
In order to explore the role of TGFβ signalling more deeply, we looked at the expression profile of 288 
TGFβ ligands as well as genes downstream of type 1 and 2 TGFβ receptor activation in high vs low 289 
density cultures. This demonstrated that high density cultures, which epithelialize normally, have 290 
low expression TGFβ pathway members (Supplementary figure 5). This is in line with the hypothesis 291 
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that TGFβ signalling is suppressed for successful epithelialization. In order to further verify this 292 
observation, we asked whether exogenous activation of the TGFβ pathway in high density cultures, 293 
which would normally have supressed TGFβ signalling, would lead to a decrease in epithelial 294 
phenotype acquisition. Recombinant TGFβ1 was added to cultures seeded at a high density of 295 
100000 cells/cm
2
 and maintained in the media for a period of 5 days. An increase in transcript 296 
expression of mesenchymal markers along with a decrease in expression of epithelial markers as 297 
measured by qPCR, was observed which suggested that activation of TGFβ signalling indeed 298 
prevented successful epithelialization (Figure 5B). This was also verified by immunostaining for 299 
expression of epithelial (PMEL17) and mesenchymal (αSMA) proteins (Figure 5C, 5D). We next tested 300 
whether the effect on phenotype was a consequence of change in cellular proliferation. Consistent 301 
with the effects seen with dbcAMP supplementation, activation of TGFβ  signalling by addition of 302 
recombinant TGFβ1 protein led to a decrease in proliferation as measured by immunostaining for 303 
Ki67 (Figure 5C, 5D). Taken together, our data supports the hypothesis that TGFβ signalling and its 304 
associated anti-proliferative effect is supressed in RPE cultures seeded at high density that acquire 305 
an epithelial phenotype. 306 
 307 
5. Screen for small molecules that positively modulate epithelialization 308 
A key requirement for a successful RPE cell replacement therapy is the scalable and efficient 309 
generation of RPE with a differentiated epithelial phenotype. In this context, identification of small 310 
molecules that could promote consistent acquisition of an epithelial phenotype even at low 311 
densities would be particularly advantageous. Therefore, we sought to leverage and extend our 312 
initial observations and look for small molecule tools that would promote epithelial phenotype 313 
acquisition at low density, a condition where RPE would not normally epithelialize. We generated a 314 
bespoke library consisting of 1000 small molecules that were known agonists or antagonists of 315 
proteins within pathways likely to affect RPE fate based on hypotheses posed by expression data or 316 
published literature indications. This included signalling pathways such as BMP, Wnt, TGFβ etc. FSK 317 
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was used as a positive control compound known to promote re-epithelialization as shown by our 318 
dbcAMP data. We established a high content immunocytochemistry based assay for PMEL17, a 319 
marker of mature pigmented RPE, in a 384 well format to allow compound screening at sufficiently 320 
high throughput with modest cell requirements. Primary screening was performed using compounds 321 
at a concentration of 10μM. A positive hit was defined as a molecule that increased % positive 322 
PMEL17 expression to greater than 3 standard deviations above the DMSO vehicle control. Effect on 323 
DAPI measurement, which is indicative of cell number, was also quantified. Data generated using 324 
these parameters allowed us to identify whether positive hits function potentially through a 325 
proliferative mode of action. Compounds that led to a significant decrease in DAPI compared to 326 
vehicle control with no effect on PMEL17 were considered toxic and ruled out from additional 327 
analysis. Data deconvolution demonstrated significant effects on PMEL17 caused by multiple 328 
inhibitors of the type 1 TGFβ receptors with a preponderance of compounds with activity against 329 
ALK5 kinase. These compounds appeared to promote epithelialization through increasing cell 330 
proliferation (i.e having an effect of increased DAPI count concomitant with increased %PMEL17). 331 
However, we did not find any mechanisms other than TGFβ signalling in this investigation. 332 
In order to verify primary hits, we extended our investigation to a broader set of ALK5 inhibitors and 333 
generated dose-response curves to measure impact on RPE phenotype by immunocytochemistry for 334 
PMEL17 (Figure 6A). We included a further assessment of cellular proliferation by quantifying the 335 
level of incorporation of EdU measured by imaging, and determined effect of compound dose on this 336 
output (Figure 6B). We determined EC50 values for both measures and noted a close correlation 337 
(R
2
=0.8) between EC50 for %PMEL17 positive and %EdU positive cells for all ALK5 inhibitors tested 338 
(Figure 6C) supporting the notion that ALK5 inhibition promotes cellular proliferation and attainment 339 
of RPE phenotype. The observed EC50 values for both PMEL17 and EdU were broadly in the same 340 
rank order as the published potencies against ALK5 for the compounds tested (Supplementary fig. 6). 341 
However, this is limited by the fact that the ALK5 potencies have not been re-measured in parallel, 342 
instead relying on literature values across different assay formats which can introduce variability. 343 
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We were also able to rule out off-target effects due to particular compound chemotypes as a 344 
consistent effect on RPE phenotype was observed with ALK5 inhibitor compounds from different 345 
chemical series. In addition, it is noteworthy that inhibitors of ALK2, a receptor for BMP ligands that 346 
signal through a distinct arm in the TGFβ cascade, had no effect on RPE phenotype indicating 347 
specificity of the ALK5 mechanism (Compound 8 (DMH1) and Compound 9 (LDN-212854) in Figure 348 
6A, 6B).  349 
To confirm that the output measure of immunostaining for PMEL17 was indicative of a true increase 350 
in epithelial RPE characteristics, we performed qPCR to measure expression of a panel of epithelial 351 
and mesenchymal markers. Compounds 6 and 7 (EC50=1.27 μM and 0.1 µM for PMEL17 respectively) 352 
were chosen as representative examples for this broader analysis. RPE were seeded at 15,000 353 
cells/cm
2
 and treated with compounds at three concentrations (10, 1 and 0.1 µM). A consistent 354 
increase in several RPE markers (BEST1, LRAT, MERTK, RPE65, RLBP1) was seen along with decrease 355 
in a marker indicative of a mesenchymal phenotype (GREM1) (Supplementary figure. 7). 356 
Measurement of these multiple endpoints provide further support to the notion that ALK5 inhibitors 357 
promote acquisition of the RPE phenotype. 358 
 359 
6. Validation of TGFβ mechanism 360 
Following on from compound screening, we wanted to independently verify the TGFβ mechanism 361 
through an orthogonal, non-chemical based interrogation. To enable this, we selected 1D11, a well-362 
characterized monoclonal pan–TGFβ-neutralizing antibody [34] to inhibit endogenous TGFβ 363 
signalling.  RPE were seeded at low density of 15000 cells/cm
2
 where TGFβ signalling should be 364 
active, and treated with neutralizing antibody for a period of 14 days. An increase in epithelial 365 
markers with an accompanying decrease in mesenchymal markers was observed at both the 366 
transcript (Figure 7A) and protein level (Figure 7B), measured by qPCR and immunocytochemistry 367 
respectively, indicating enhanced uptake of epithelial characteristics. We also observed an increase 368 
in proliferation as measured by imaging of EdU incorporation, confirming that suppression of TGFβ 369 
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signalling led to enhanced proliferation (Figure 7B). Taken together, our data is consistent with the 370 
hypothesis that TGFβ signalling serves to impede epithelial phenotype acquisition in RPE and that its 371 
inhibition can lead to enhanced uptake of epithelial identity. 372 
 373 
DISCUSSION:  374 
Stem cells provide a potentially unlimited source of cells for regenerative therapy in a range of 375 
human disorders including retinal diseases such as age-related macular degeneration (AMD). AMD is 376 
the leading cause of blindness in people over the age of 65 in the developed world. It is a progressive 377 
disease caused by death and dysfunction of the retinal pigment epithelium (RPE) which in turn leads 378 
to photoreceptor loss. The specific loss of the RPE monolayer, combined with other advantages of 379 
targeting this particular tissue (immune privileged niche, ease of accessibility, separation from 380 
systemic circulation, well established methods for diagnosis and monitoring progression) suggests 381 
AMD as a prime candidate for exploring replacement of the damaged RPE monolayer with stem cell 382 
derived healthy RPE as a therapy [35-38].  383 
The RPE monolayer, formed in the early embryo, is a terminally differentiated cell sheet which 384 
develops with a centre to periphery gradient such that only the peripheral cells retain low levels of 385 
proliferation whereas the remainder remains non-proliferative throughout life [39, 40]. However, in 386 
culture, their normal quiescence can be released resulting in a re-entry into the cell-cycle 387 
accompanied by proliferation. This results in trans-differentiation where cells deviate from an 388 
epithelial state and instead express hallmarks of a fusiform, mesenchymal state. This is followed by a 389 
mesenchymal-epithelial transition (MET) regulated by the transcription factor FOXM1 which results 390 
in re-epithelialization [18]. However, this process is density dependent, where cells seeded at an 391 
appropriately high density, successfully acquire an epithelial phenotype. Cultures seeded at low 392 
density fail to attain the epithelial state and instead continue to remain mesenchymal. Taking 393 
advantage of the critical seeding-density dependent nature of the culture, we wanted to gain further 394 
understanding of the signalling pathways that control the transition and acquisition of the epithelial 395 
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phenotype. This would allow us to interrogate pathways of interest and hence promote epithelial 396 
fate achievement and increased RPE yield.  397 
In the first instance, we have shown that manipulating cAMP levels significantly impacts on the re-398 
attainment of the RPE phenotype in a time- and density-dependent manner. Published literature 399 
suggested that cAMP exerts direct effects on RPE phenotypes such as pigmentation and 400 
phagocytosis while inhibiting RPE proliferation [25, 26]. We show that elevating cAMP levels in 401 
dissociated RPE cells through FSK treatment or use of the cell permeant cAMP analogue dbcAMP, 402 
increases acquisition of RPE phenotype through increasing proliferation. Remarkably, global gene 403 
expression profiling suggests that dbcAMP supplementation promotes RPE epithelialization to mimic 404 
a doubling of seeding density compared to cells without supplementation. This is of particular 405 
relevance in terms of RPE yield while manufacturing cells for a clinical application e.g culturing 406 
transplantation-ready cells under GMP compatible conditions for a clinical trial.  In such a case, 407 
modulation of cAMP signalling through the use of dbcAMP could equate to a 100% increase in cell 408 
yield and consequently affect cost and feasibility of the cell replacement therapy approach. It is 409 
important to appreciate that, instead of uncontrolled proliferation, our data is consistent with the 410 
interpretation that in vitro RPE culture is a homeostatic system where cell contact signals the cells to 411 
terminate proliferation and achieve quiescence [40]. This is distinct from contexts where increased 412 
proliferation could lead to potentially detrimental impacts, e.g. when RPE cell monolayers are not 413 
anchored and cells at the edge of a monolayer could proliferate and acquire a mesenchymal identity 414 
without these critical inhibitory signals from other RPE cells. An ocular pathology where this occurs is 415 
PVR, where proliferation of cell types including RPE, together with the appearance of a 416 
mesenchymal, migratory RPE state, results in the formation of a fibrotic, contractile scar tissue 417 
which inhibits vision [41]. Interestingly, one of the key pathways that have been implicated in PVR 418 
formation and progression is TGFβ signalling [42, 43]. TGFβ acts as a potent driver of fibrosis 419 
progression through the induction of epithelial–mesenchymal transition (EMT), in which epithelial 420 
cells acquire mesenchymal phenotypes, leading to enhanced motility and invasion [44]. Given the 421 
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precedence of TGFβ in pathogenesis of PVR, we were intrigued that analysis of gene expression 422 
upon cAMP elevation identified a potential role of this pathway in epithelial fate acquisition. We 423 
chose to investigate this in the context of a phenotypic screening approach where RPE seeded at low 424 
density, which would normally not epithelialize, were challenged with a focused library of small 425 
molecules targeting signalling pathways of interest, including but not limited to TGFβ signalling. We 426 
then looked for those molecules which could promote acquisition of the epithelial phenotype at low 427 
density and retrospectively used their known target activities to inform on the signalling pathway 428 
that could be involved. To our knowledge, this study provides the first example of use of hESC-429 
derived RPE cells for high throughput phenotypic screening, successfully miniaturized to a 384 well 430 
format, and highlights that this clinically applied cell type is amenable to such interrogations. This 431 
approach led us to confirm the role of the TGFβ pathway, specifically signalling through the ALK5 432 
receptor, as being key to RPE epithelial fate acquisition. TGFβ signalling controls a plethora of 433 
cellular responses and plays an important role in animal development. Its biological activity has been 434 
implicated in epithelial-mesenchymal interactions, e.g., in branching morphogenesis of the lung, 435 
kidney, mammary gland, and in inductive events between mammary epithelium and stroma [28, 45, 436 
46]. Several studies in diverse cell types show that activation of TGFβ signalling leads to inhibition of 437 
cell proliferation and an increase in migration and uptake of mesenchymal characteristics [47, 48]. 438 
Polarized, functional RPE express and secrete low levels of TGFβ ligands to maintain the normal 439 
physiology of the subretinal space. Pathological conditions such as PVR lead to loss of polarity which 440 
manifests in high level of TGFβ secretion and loss of epithelial integrity and function [49, 50]. Our 441 
results suggest that inhibition of the TGFβ pathway via ALK5 signalling with small molecules 442 
effectively promotes the attainment of the epithelial state of RPE in a proliferation-dependent 443 
manner which potentially allows more favourable cell-cell contacts and promotes epithelialization in 444 
a manner akin to that of cAMP. Additionally, use of multiple compound chemotypes as well as 445 
recapitulating the same results with an orthogonal, antibody based neutralization method further 446 
lends support to the key role of TGFβ signalling. Based on our data which shows that TGFβ signalling 447 
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is downregulated in high density cultures, we propose that use of ALK5 inhibitors will promote 448 
proliferation and yield when used in cultures at low density, where this signalling pathway is active. 449 
This would translate to a bonafide increase in RPE yield as these cultures would normally not re-450 
epithelialize in the absence of these compounds.  However, further work is needed to fully 451 
characterize the activity of molecules and to understand their potency and specificity for the various 452 
TGFβ receptor subtypes in a head-to-head comparison. It also remains to be tested how cAMP 453 
elevation mechanistically inhibits the TGFβ pathway to potentiate RPE re-epithelialization. It is 454 
possible that increased cAMP signalling leads to PKA activation which in turn antagonizes the 455 
ras/MEK/ERK signaling cascade leading to attenuation of TGFβ signalling, as has been described in 456 
other cellular models [51-55]. This hypothesis requires further investigation to be validated. 457 
Another area that warrants further exploration is to test whether additional pathways that control 458 
TGFβ signalling e.g the Hippo and Crumbs pathway which are key sensors of cell density [56] and 459 
hence may be relevant to cell contact dependent RPE epithelialization, also play a role in this 460 
process. This will help to fully comprehend how proliferation dependent cell-cell contacts signal the 461 
initiation of the epithelialization program and how a network of signalling pathways feed into it.  462 
 463 
CONCLUSION 464 
To conclude, in order to transition to a successful and efficacious cell replacement therapy, stem cell 465 
derived RPE need to be produced at scale with high yield and under GMP conditions. Presence of 466 
trans-differentiated RPE exhibiting mesenchymal characteristics that develop upon seeding cultures 467 
at low density can potentially compromise the functionality of the cell population. Given the 468 
intricate link between seeding density and epithelial fate outcome, the use of small molecule tools 469 
for e.g dbcAMP or inhibitors of TGFβ signalling as demonstrated in this report, could support large 470 
scale manufacturing of functional RPE with high yield which would be advantageous for successful 471 
clinical translation and therapeutic output. 472 
 473 
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 647 
FIGURE LEGENDS 648 
Fig 1: Cell-density dependent effects on re-epithelialization in stem-cell derived RPE 649 
A. Schematic representation of density-dependent RPE culture where RPE seeded at high density 650 
undergo proliferation and successfully epithelialize whereas RPE seeded at low density remain 651 
mesenchymal. 652 
B. Heatmap of expression profiles of the top 250 expressed genes ranked by the significance of their 653 
expression changes over time in high (100000 cells/cm
2
) and low (8000 cells/cm
2
) density cultures. 654 
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Raw expression data are mean centred and scaled to unit variance prior to clustering. The genes 655 
cluster into two groups (1 & 2) based on the observed expression pattern. Cluster 1 genes show 656 
initial downregulation whereas Cluster 2 genes show initial upregulation upon dissociation and 657 
culture. Genes from both clusters return to basal levels with time upon high density seeding but not 658 
upon low density seeding.  659 
C. Heatmap showing changes in gene expression of a panel of representative epithelial and 660 
mesenchymal markers over a timecourse of RPE culture where cells are seeded as in Figure 1B. 661 
D. Representative images showing immunocytochemistry for epithelial (CRALBP, ZO1, PMEL17) and 662 
mesenchymal markers (α-SMA) at day 42 in cultures seeded as in Figure 1B. 663 
 664 
Fig 2: Increasing cAMP signalling promotes acquisition of RPE identity across multiple cell 665 
densities.  666 
A. Representative brightfield images showing  RPE seeded at multiple densities in the presence or 667 
absence of  10μM forskolin treatment at day 63 in culture 668 
B. ‘The RPE Score’ (see main text) of each sample in the presence (blue) and absence (red) of 10μM 669 
FSK at day 63 is plotted against the seeding density (2.5k, 10k, 15k, 20k, 25k, 27.5k, 30k, 38k; 670 
k=x1000cells/cm
2
). The shaded area represents 95% confidence intervals and the solid circles 671 
represent biological replicates at the given density.  672 
 673 
Fig 3: Gene expression analysis of dbcAMP treated RPE. 674 
A. Principal component analysis of the microarray gene expression data is shown for samples 675 
obtained from three different seeding densities (indicated by the shape of each point: circle= 10000 676 
cells/cm
2
; square= 20000 cells/cm
2
 and diamond= 40000 cells/cm
2
) in the presence (blue) or absence 677 
(red) of dbcAMP. The data from four time points (Day 0, 3, 15 and 34 post-seeding) is indicated by 678 
the shading of each point and the labelled ellipses such that colour intensity increases with 679 
increasing time in culture. The day 0 samples are indicated as black points and the proportion of the 680 
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total variance captured by each principal component is indicated in the axis title. This shows that at 681 
each time point tested, there is a ‘doubling effect’ i.e clustering of samples seeded at half the 682 




B. Heatmap of gene expression levels for the top 1% most variable genes (rows) observed at day 34 685 
in culture. The seeding density and dbcAMP treatment status each sample is indicated by the labels 686 
at the bottom of the heatmap (k= x1000 cells/cm
2
). Expression levels are shown mean centred and 687 
scaled to unit variance for each gene. Clustering of samples consistent with the doubling effect can 688 
be seen.  689 
C. Heatmap of gene expression levels for selected RPE markers across all timepoints, seeding density 690 
and dbcAMP treatment is shown.  691 
 692 
Fig 4: dbcAMP increases proliferation of RPE cells 693 
A. Exemplar gene ontology (GO) terms, derived from comparison of cultures in the presence vs. 694 
absence of dbcAMP at Day34 (20000 cells/cm
2
 seeding density), alongside their gene set test 695 
significance p values (p < 0.05). D= Downregulated, U= Upregulated. FDR= False discovery rate. 696 
B. Representative images showing EdU incorporation in the presence or absence of dbcAMP in RPE 697 
seeded at 38000 cells/cm
2
 at different timepoints in culture. The quantification of EdU incorporation 698 
is shown below. Bars represent Mean + SD (n=8). 699 
C. Representative images showing immunocytochemistry for Ki67 in the presence or absence of 700 
10μM FSK in RPE seeded at 38000 cells/cm
2
 at different timepoints in culture. The quantification of 701 
images is shown below. Bars represent Mean + SD (n=3). 702 
D. Representative images showing nuclei stained with DAPI in RPE treated seeded at 38000 703 
cells/cm2 and cultured for a period of 8 weeks with different periods of exposure to dbcAMP 704 
Quantification of cell number, measured by DAPI positive nuclei per frame imaged is shown below. 705 
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(Vehicle: media alone, 2+6: 2wk dbcAMP+ 6wk media, 3+5: 3wk dbcAMP+ 5wk media, 8: 8wk 706 
dbcAMP). Bars represent Mean + SD (n=3).  707 
 708 
 Fig 5: Role of TGFβ signalling in RPE 709 
A. Histogram showing change in expression of SMAD3 bound genes in dbcAMP vs control cultures at 710 
day 34 (20000 cells/cm
2
 seeding density) . The frequency of genes is plotted on the y axis and the log 711 
fold change is plotted on the x axis (No change= 0 log fold change). The leftward shift of the 712 
distribution indicates a significant decrease in expression of SMAD3 responsive genes with dbcAMP 713 
treatment.  714 
B. qPCR based measurement of transcript expression of a panel of epithelial (CRB3, BEST1, PMEL) 715 
and mesenchymal (CDH2, MMP2, GREM1) markers in cells seeded at 100000 cells/cm
2
 and exposed 716 
to 10ng/ml TGFβ1 for 5 days. ATP5B and CYC1 are used as housekeeping genes. Bars represent 717 
Mean + SD (n=3). P<0.05 (Student’s t-test).  718 
C Representative images showing immunocytochemistry for indicated markers (in cells seeded at 719 
high density and exposed to TGFβ1 for 5 days. 720 
D. Quantification of Figure 5C 721 
 722 
Fig 6: Effect of ALK5 inhibitors on RPE phenotype and proliferation  723 
Cells were seeded at 15000 cells/cm
2
 and treated with compounds for 14 days. 724 
Immunocytochemistry was performed and dose response curves were generated measuring % of 725 
DAPI positive cells staining positive for PMEL17 (A) and EdU (B). Forskolin (FSK) was used as the 726 
positive control. Correlation between EC50 for both measures for all ALK5 inhibitors screened is 727 
shown in (C). 728 
 729 
Fig 7: Inhibition of TGFβ signalling promotes RPE phenotype 730 
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A. qPCR based measurement of transcript expression of a panel of epithelial (BEST1, PMEL, LRAT, 731 
MERTK, RPE65, RLBP1) and mesenchymal (GREM1) markers in RPE seeded at 5000 cells/cm
2
 and 732 
treated with 10μg/ml Anti-TGFβ antibody (1D11) for a period of 14 days. Data is normalized to 733 
expression of vehicle control. HPRT1 is used as a housekeeping gene.  Bars represent Mean + SD 734 
(n=3). P<0.05 (Student’s t-test). 735 
B. Representative images showing immunocytochemistry for indicated markers along with their 736 
quantification in cells seeded at 5000 cells/cm
2
 and exposed to 10µg/ml Anti-TGFβ for 14 days. 737 
 738 
SUPPLEMENTARY FIGURE LEGENDS 739 
Supplementary Figure1 740 
A. Representative confocal images of X-Z cross-sections of RPE cells cultured on transwells 741 
immunostained for ZO1, MERTK and PMEL17 (green). Nuclei are stained with DAPI (blue). 742 
Autofluorescence can also be seen from the polyester membrane of the transwell and has been 743 
indicated within dotted white lines. 744 
B. Representative confocal image showing phagocytosis of fluorescent bead (red) by RPE. RPE grown 745 
on transwells were incubated with polystyrene beads for a period of 24h at 37
ο
C. The transwell 746 
membrane was immunostained for CRALBP (green) to show RPE coverage membrane and sectioned. 747 
The beads can be seen within the CRALBP positive area but outside the nuclei stained with DAPI 748 
(blue) indicating internalization by phagocytosis. 749 
C. Spent media was collected from RPE and ARPE19 cultures seeded on transwells at Day 4 (RPE) and 750 
Day 21 (RPE, ARPE19). VEGF and PEDF were quantified to show that their secretion increases with 751 
time in culture. Bars represent Mean+ SD (n=4-6). P<0.05, Student’s t-test. 752 
Supplementary Figure2:  753 
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Increasing cAMP signalling promotes acquisition of RPE identity across multiple cell densities. 754 
Increased pigmentation and cell coverage with forskolin treatment are evident in cells and cell 755 
lysates. (K= x1000) 756 
 757 
Supplementary Figure 3: 758 
A. Heatmap showing clustering of expression of epithelial and mesenchymal markers, as measured 759 
by qPCR, where epithelial marker genes cluster together and are distinct from mesenchymal 760 
markers. qPCR data from samples seeded at 38000 cells/cm
2 
 in media at Day63 in culture were used 761 
to generate this heatmap. Gene specific qPCR showing effect of FSK on expression of epithelial (B, C) 762 
and mesenchymal markers (D, E) across a range of densities at Day63 is shown.  763 
Supplementary Figure 4:  764 
A. qPCR based measurement of transcript expression of a panel of RPE markers in cells seeded at 765 
different densities (10k, 20k, 40k; k=1000 cells/cm
2
) at day 3, 15, 34 (D3, D15, D34) in culture in the 766 
presence (+) or absence (-) of 0.5mM dbcAMP. GAPDH and ACT are used as a housekeeping genes.  767 
Bars represent Mean + SD (n=3). P<0.05 (Student’s t-test). 768 
B. Representative images showing immunocytochemistry for epithelial marker PMEL17 (green) at 769 
day 15 in cultures seeded as above in the presence or absence of dbcAMP. Nuclei are counterstained 770 
with DAPI (blue).  771 
C. dbcAMP dose of at least 0.5mM is required to observe effect on RPE phenotype. RPE were seeded 772 
at 20000 cells/cm
2
 and treated with different concentrations of dbcAMP for a period of 14 days. 773 
Immunocytochemistry was performed for PMEL17 which showed that a concentration of at least 774 
0.5mM dbcAMP was required to observe an upregulation of this marker of RPE phenotype. (n=3, 775 
Bars= + SD) 776 
Supplementary Figure 5:  777 
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Schematic of the TGFβ signalling pathway. The downstream signalling effectors are coloured 778 
according to their differential expression in high density vs low density cultures. Red indicates 779 
decreased expression and green indicates increased expression in high vs. low density cultures with 780 
the intensity of the shade indicating fold change. Low expression of TGFβ and its downstream 781 
effectors, as seen by red shading, suggests suppression of the TGFβ pathway in high density cultures 782 
compared to low density cultures.  783 
Supplementary Figure 6:  784 
Table summarizing published IC50 values against ALK5 and ALK2 for compounds tested [57-61], 785 
compound structures and EC50 values for effect on %PMEL17 and %EdU measured by 786 
immunocytochemistry (calculated in this study).  787 
Supplementary Figure 7: 788 
qPCR based measurement of transcript expression of a panel of epithelial  (BEST1, LRAT, MERTK, 789 
RPE65, RLBP1) and mesenchymal (GREM1) markers in RPE seeded at 15000 cells/cm
2
 and treated 790 
with Compound #6 and #7 at a concentration of 10μM, 1μM and 0.1μM for a period of 14 days. Data 791 
is normalized to expression of vehicle control. GAPDH and HPRT1 are used as housekeeping genes. 792 
Supplementary Table 1: 793 
Table showing list of genes in Cluster 1 and Cluster 2 from Figure 1B.  794 
Supplementary Table 2: 795 
Table showing list of GO terms upregulated in the presence of dbcAMP in cultures seeded at 20000 796 
cells/cm
2 
at Day 34. 797 
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ILMN_1733288C1RL 51279 1
ILMN_1677603C1S 716 1
ILMN_2049727C 0orf111 51526 1
ILMN_1703839C20orf186 149954 1
ILMN_1751228C 0orf46 55321 1
ILMN_2411127C 1orf57 54059 1
ILMN_1695959C21orf63 59271 1
ILMN_1767601C2 orf94 246705 1
ILMN_1737255C22orf36 388886 1
ILMN_3248551C2CD4B 388125 1
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ILMN_1801118C 6orf33 79622 2
ILMN_1656452C16orf59 80178 2
ILMN_1729450C16orf62 57020 2
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ILMN_1658290C16orf68 79091 2
ILMN_1790537C16orf75 116028 2
ILMN_2179726C1 orf93 90835 2
ILMN_1776490C17orf53 78995 2
ILMN_2221076C17orf85 55421 2
ILMN_2390310C 7orf91 84981 2
ILMN_1690442C18orf45 85019 2
ILMN_1717793C19orf33 64073 2













ILMN_1749915C orf63 57035 2
ILMN_1698243C1orf85 112770 2
ILMN_1662640C2 orf127 140851 2
ILMN_1697363C20orf27 54976 2
ILMN_1699071C2 orf7 56911 2











ILMN_1790461C orf125 84300 2
ILMN_1815039C6orf153 88745 2
ILMN_1763907C6orf173 387103 2
ILMN_2134765C orf26 401251 2
ILMN_1665117C6orf89 221477 2
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ILMN_1803317C9orf114 51490 2
ILMN_1723709C9orf116 138162 2
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ILMN_1698533IDH3A 3419 2
ILMN_1755075IDI1 3422 2
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ILMN_1808789MYO5C 55930 2
ILMN_1672547MYO9B 4650 2

































































































































































































































































































































ILMN_1679322SH D4A 63898 2
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Gene Ontology terms derived from comparing gene expression data of RPE seeded at 20000 cells/cm2 in the presence vs absence of dbcAMP at Day35 in culture.
ID up.FDR dn.FDR mx.FDR term ontology
GO:1901615 2.93E-12 1 0.00017 organic hydroxy compound metabolic process BP
GO:0044282 4.42E-11 1 0.002263 small molecule catabolic process BP
GO:0016054 1.12E-08 1 0.009777 organic acid catabolic process BP
GO:0046395 1.12E-08 1 0.009777 carboxylic acid catabolic process BP
GO:0009063 1.58E-08 1 0.037714 cellular amino acid catabolic process BP
GO:0007059 2.00E-07 1 0.258102 chromosome segregation BP
GO:0007067 2.77E-07 1 0.079368 mitotic nuclear division BP
GO:0006066 4.39E-07 1 0.009254 alcohol metabolic process BP
GO:1901616 9.79E-06 1 0.082887 organic hydroxy compound catabolic process BP
GO:1901606 1.41E-05 1 0.145533 alpha-amino acid catabolic process BP
GO:0071825 1.43E-05 1 0.043816 protein-lipid complex subunit organization BP
GO:0019748 2.32E-05 1 3.52E-07 secondary metabolic process BP
GO:0031110 3.23E-05 1 0.11038 regulation of microtubule polymerization or depolymerizationBP
GO:0034308 3.61E-05 1 2.62E-05 primary alcohol metabolic process BP
GO:0050953 4.08E-05 1 0.071441 sensory perception of light stimulus BP
GO:0009083 4.16E-05 1 0.058766 branched-chain amino acid catabolic process BP
GO:1901617 4.32E-05 1 0.002931 organic hydroxy compound biosynthetic process BP
GO:0046164 4.81E-05 1 0.085481 alcohol catabolic process BP
GO:0071827 4.88E-05 1 0.047132 plasma lipoprotein particle organization BP
GO:0007601 5.31E-05 1 0.059793 visual perception BP
GO:0002455 6.08E-05 1 0.046003 humoral immune response mediated by circulating immunoglobulinBP
GO:0070507 6.36E-05 1 0.054153 regulation of microtubule cytoskeleton organizationBP
GO:0006575 6.49E-05 1 0.012817 cellular modified amino acid metabolic process BP
GO:0034331 7.70E-05 1 0.010312 cell junction maintenance BP
GO:0042440 9.10E-05 1 0.019981 pigment metabolic process BP
GO:0051186 9.10E-05 1 0.154509 cofactor metabolic process BP
GO:0043691 9.32E-05 1 0.015928 reverse cholesterol transport BP
GO:0044283 9.49E-05 1 0.00213 small molecule biosynthetic process BP
GO:00970060.000103 1 0.097365 regulation of plasma lipoprotein particle levels BP
GO:00311090.000113 1 0.240483 microtubule polymerization or depolymerization BP
GO:00000700.000118 1 0.250392 mitotic sister chromatid segregation BP
GO:00439540.000152 1 0.438828 cellular component maintenance BP
GO:00508730.000156 1 0.006572 brown fat cell differentiation BP
GO:00067660.000215 1 0.013412 vitamin metabolic process BP
GO:00067320.000222 1 0.151493 coenzyme metabolic process BP
GO:00447820.000225 1 0.503954 cilium organization BP
GO:00328860.000236 1 0.047584 regulation of microtubule-based process BP
GO:19016050.000257 1 0.007444 alpha-amino acid metabolic process BP
GO:00226160.000268 1 0.438671 DNA strand elongation BP
GO:00070190.000272 1 0.087457 microtubule depolymerization BP
GO:00008190.000305 1 0.23304 sister chromatid segregation BP
GO:00090810.000312 1 0.14558 branched-chain amino acid metabolic process BP
GO:00157110.000335 1 0.003621 organic anion transport BP
GO:00189580.000335 1 0.125141 phenol-containing compound metabolic process BP
GO:00461480.000358 1 0.053141 pigment biosynthetic process BP
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GO:00065200.000414 1 0.006592 cellular amino acid metabolic process BP
GO:00302610.000453 1 0.547212 chromosome condensation BP
GO:00063100.000471 1 0.902242 DNA recombination BP
GO:00068200.000492 1 0.000414 anion transport BP
GO:00069580.000509 1 0.050892 complement activation, classical pathway BP
GO:00062710.000533 1 0.386653 DNA strand elongation involved in DNA replicationBP
GO:00311110.000584 1 0.121348 negative regulation of microtubule polymerization or depolymerizationBP
GO:00000960.000647 1 0.368923 sulfur amino acid metabolic process BP
GO:00343750.000721 1 0.044579 high-density lipoprotein particle remodeling BP
GO:00160520.000774 1 0.780692 carbohydrate catabolic process BP
GO:00343670.000816 1 0.017031 macromolecular complex remodeling BP
GO:00343680.000816 1 0.017031 protein-lipid complex remodeling BP
GO:00343690.000816 1 0.017031 plasma lipoprotein particle remodeling BP
GO:00066310.000832 1 0.017947 fatty acid metabolic process BP
GO:00447240.000898 1 0.739163 single-organism carbohydrate catabolic process BP
GO:00065820.000966 1 7.30E-05 melanin metabolic process BP
GO:0031055 0.001 1 0.310853 chromatin remodeling at centromere BP
GO:00602710.001062 1 0.478125 cilium morphogenesis BP
GO:00067670.001199 1 0.141344 water-soluble vitamin metabolic process BP
GO:00068050.001226 1 0.006221 xenobiotic metabolic process BP
GO:00070260.001226 1 0.123191 negative regulation of microtubule depolymerizationBP
GO:00714660.001226 1 0.006221 cellular response to xenobiotic stimulus BP
GO:19030460.001226 1 0.683949 meiotic cell cycle process BP
GO:00345080.001256 1 0.391878 centromere complex assembly BP
GO:19013790.001306 1 0.498682 regulation of potassium ion transmembrane transportBP
GO:00091130.001619 1 0.406133 purine nucleobase biosynthetic process BP
GO:00423840.001703 1 0.576318 cilium assembly BP
GO:00970670.001774 1 0.065497 cellular response to thyroid hormone stimulus BP
GO:00160420.001856 1 0.099453 lipid catabolic process BP
GO:00062810.001884 1 0.833241 DNA repair BP
GO:00060990.001923 1 0.950707 tricarboxylic acid cycle BP
GO:00064150.001923 1 1 translational termination BP
GO:0016125 0.00207 1 0.132192 sterol metabolic process BP
GO:00060900.002073 1 0.678514 pyruvate metabolic process BP
GO:00061030.002078 1 0.536971 2-oxoglutarate metabolic process BP
GO:00091610.002475 1 1 ribonucleoside monophosphate metabolic processBP
GO:00108780.002489 1 0.105148 cholesterol storage BP
GO:00337000.002511 1 0.131008 phospholipid efflux BP
GO:0006081 0.00275 1 6.65E-05 cellular aldehyde metabolic process BP
GO:00311140.002774 1 0.241597 regulation of microtubule depolymerization BP
GO:00094100.002926 1 0.006427 response to xenobiotic stimulus BP
GO:00063360.002991 1 0.518331 DNA replication-independent nucleosome assemblyBP
GO:00347240.002991 1 0.518331 DNA replication-independent nucleosome organizationBP
GO:0009126 0.00309 1 1 purine nucleoside monophosphate metabolic processBP
GO:0009167 0.00309 1 1 purine ribonucleoside monophosphate metabolic processBP
GO:00060690.003268 1 0.119241 ethanol oxidation BP
GO:00448390.003326 1 0.291271 cell cycle G2/M phase transition BP
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GO:00067490.003327 1 0.045138 glutathione metabolic process BP
GO:00424380.003339 1 0.000108 melanin biosynthetic process BP
GO:00723290.003369 1 0.065993 monocarboxylic acid catabolic process BP
GO:00340800.003464 1 0.34497 CENP-A containing nucleosome assembly BP
GO:00616410.003464 1 0.34497 CENP-A containing chromatin organization BP
GO:00464700.003583 1 0.530882 phosphatidylcholine metabolic process BP
GO:00062700.003597 1 0.268081 DNA replication initiation BP
GO:00000860.003634 1 0.304246 G2/M transition of mitotic cell cycle BP
GO:00487120.003649 1 0.176709 negative regulation of astrocyte differentiation BP
GO:00432660.003678 1 0.298474 regulation of potassium ion transport BP
GO:00445500.003726 1 6.08E-05 secondary metabolite biosynthetic process BP
GO:00090600.003752 1 0.927741 aerobic respiration BP
GO:00461650.003867 1 0.15834 alcohol biosynthetic process BP
GO:0007131 0.00403 1 1 reciprocal meiotic recombination BP
GO:0035825 0.00403 1 1 reciprocal DNA recombination BP
GO:00069560.004174 1 0.150685 complement activation BP
GO:00461120.004235 1 0.627265 nucleobase biosynthetic process BP
GO:00323730.004283 1 0.065847 positive regulation of sterol transport BP
GO:00323760.004283 1 0.065847 positive regulation of cholesterol transport BP
GO:00071260.004557 1 0.879553 meiotic nuclear division BP
GO:00466550.004557 1 0.15776 folic acid metabolic process BP
GO:00333440.004639 1 0.166234 cholesterol efflux BP
GO:00436480.005157 1 0.433678 dicarboxylic acid metabolic process BP
GO:00070880.005166 1 0.300971 regulation of mitosis BP
GO:00067330.005188 1 0.622461 oxidoreduction coenzyme metabolic process BP
GO:00107450.005235 1 0.141063 negative regulation of macrophage derived foam cell differentiationBP
GO:00108850.005257 1 0.153065 regulation of cholesterol storage BP
GO:00193950.005262 1 0.328246 fatty acid oxidation BP
GO:00002260.005336 1 0.115782 microtubule cytoskeleton organization BP
GO:00723370.005425 1 0.364794 modified amino acid transport BP
GO:00506670.005552 1 0.441374 homocysteine metabolic process BP
GO:2000179 0.00563 1 0.136952 positive regulation of neural precursor cell proliferationBP
GO:0006298 0.0057 1 0.771975 mismatch repair BP
GO:0010765 0.0057 1 0.095484 positive regulation of sodium ion transport BP
GO:19010160.005717 1 0.731569 regulation of potassium ion transmembrane transporter activityBP
GO:00060960.005734 1 0.69149 glycolytic process BP
GO:0006720 0.00587 1 0.000193 isoprenoid metabolic process BP
GO:00033330.005871 1 0.035314 amino acid transmembrane transport BP
GO:00718710.005873 1 0.027937 response to epinephrine BP
GO:00650050.005875 1 0.541208 protein-lipid complex assembly BP
GO:00469420.006059 1 0.008481 carboxylic acid transport BP
GO:00434860.006074 1 0.28565 histone exchange BP
GO:00424390.006178 1 0.479505 ethanolamine-containing compound metabolic processBP
GO:00427540.006178 1 0.125408 negative regulation of circadian rhythm BP
GO:00718750.006392 1 0.314448 adrenergic receptor signaling pathway BP
GO:0000098 0.00645 1 0.245485 sulfur amino acid catabolic process BP
GO:00082030.006816 1 0.142462 cholesterol metabolic process BP
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GO:00107420.007102 1 0.186422 macrophage derived foam cell differentiation BP
GO:00900770.007102 1 0.186422 foam cell differentiation BP
GO:00158490.007413 1 0.007849 organic acid transport BP
GO:00487100.007466 1 0.008213 regulation of astrocyte differentiation BP
GO:00344400.007706 1 0.298237 lipid oxidation BP
GO:00090700.007908 1 0.704198 serine family amino acid biosynthetic process BP
GO:00060670.008175 1 0.032526 ethanol metabolic process BP
GO:00456850.008213 1 0.03292 regulation of glial cell differentiation BP
GO:00513210.008392 1 0.791268 meiotic cell cycle BP
GO:00065760.008571 1 0.538139 cellular biogenic amine metabolic process BP
GO:00432410.008799 1 0.84473 protein complex disassembly BP
GO:19029320.008805 1 0.096018 positive regulation of alcohol biosynthetic processBP
GO:00469160.008832 1 0.516754 cellular transition metal ion homeostasis BP
GO:00160530.008894 1 0.022671 organic acid biosynthetic process BP
GO:00463940.008894 1 0.022671 carboxylic acid biosynthetic process BP
GO:0007051 0.00892 1 0.061413 spindle organization BP
GO:00161260.009027 1 0.609909 sterol biosynthetic process BP
GO:00068650.009071 1 0.000694 amino acid transport BP
GO:00064140.009175 1 1 translational elongation BP
GO:00156720.009309 1 0.058139 monovalent inorganic cation transport BP
GO:0035418 0.00944 1 0.169143 protein localization to synapse BP
GO:00331730.009584 1 0.204049 calcineurin-NFAT signaling cascade BP
GO:0000188 1 0.004988 0.595475 inactivation of MAPK activity BP
GO:0000768 1 0.009337 0.240799 syncytium formation by plasma membrane fusionBP
GO:0001501 1 2.18E-06 3.74E-05 skeletal system development BP
GO:0001525 1 1.38E-06 1.85E-08 angiogenesis BP
GO:0001569 1 6.08E-05 0.001478 patterning of blood vessels BP
GO:0001667 1 0.000417 2.45E-07 ameboidal cell migration BP
GO:0001704 1 0.00111 0.003684 formation of primary germ layer BP
GO:0001763 1 0.000266 1.17E-06 morphogenesis of a branching structure BP
GO:0001817 1 0.001386 0.040764 regulation of cytokine production BP
GO:0001933 1 0.002133 0.001452 negative regulation of protein phosphorylation BP
GO:0001952 1 0.007647 0.027937 regulation of cell-matrix adhesion BP
GO:0002009 1 0.006484 1.64E-09 morphogenesis of an epithelium BP
GO:0002063 1 0.000262 0.081645 chondrocyte development BP
GO:0002369 1 0.007992 0.300971 T cell cytokine production BP
GO:0002429 1 0.00018 0.482575 immune response-activating cell surface receptor signaling pathwayBP
GO:0002431 1 6.37E-06 0.898861 Fc receptor mediated stimulatory signaling pathwayBP
GO:0002433 1 6.36E-06 0.924106 immune response-regulating cell surface receptor signaling pathway involved in phagocytosisBP
GO:0002474 1 0.00035 0.537427 antigen processing and presentation of peptide antigen via MHC class IBP
GO:0002478 1 0.001509 0.004735 antigen processing and presentation of exogenous peptide antigenBP
GO:0002479 1 0.001628 0.450224 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentBP
GO:0002521 1 0.006959 0.017595 leukocyte differentiation BP
GO:0002694 1 0.006754 0.164184 regulation of leukocyte activation BP
GO:0002696 1 9.90E-05 0.432886 positive regulation of leukocyte activation BP
GO:0002702 1 0.006869 0.874259 positive regulation of production of molecular mediator of immune responseBP
GO:0002720 1 0.00854 0.923761 positive regulation of cytokine production involved in immune responseBP
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GO:0002757 1 0.000281 0.518726 immune response-activating signal transduction BP
GO:0002764 1 9.81E-06 0.142808 immune response-regulating signaling pathway BP
GO:0002768 1 4.23E-05 0.19906 immune response-regulating cell surface receptor signaling pathwayBP
GO:0003094 1 0.000566 0.044497 glomerular filtration BP
GO:0006029 1 0.000259 0.006965 proteoglycan metabolic process BP
GO:0006469 1 0.001433 0.02517 negative regulation of protein kinase activity BP
GO:0006486 1 0.000186 0.402251 protein glycosylation BP
GO:0006487 1 1.16E-05 0.157727 protein N-linked glycosylation BP
GO:0006888 1 4.97E-05 0.049947 ER to Golgi vesicle-mediated transport BP
GO:0006890 1 0.001012 0.906512 retrograde vesicle-mediated transport, Golgi to ERBP
GO:0006892 1 0.002143 0.796339 post-Golgi vesicle-mediated transport BP
GO:0006895 1 0.004334 0.92091 Golgi to endosome transport BP
GO:0006900 1 0.00034 0.083326 membrane budding BP
GO:0006901 1 0.000164 0.069687 vesicle coating BP
GO:0006903 1 0.000158 0.04932 vesicle targeting BP
GO:0006909 1 0.000185 0.010056 phagocytosis BP
GO:0006914 1 0.005742 0.685629 autophagy BP
GO:0006977 1 0.007736 0.233809 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestBP
GO:0006984 1 8.33E-11 5.05E-06 ER-nucleus signaling pathway BP
GO:0006986 1 1.56E-10 0.001293 response to unfolded protein BP
GO:0006987 1 7.24E-13 1.96E-05 activation of signaling protein activity involved in unfolded protein responseBP
GO:0007015 1 7.14E-05 0.001476 actin filament organization BP
GO:0007029 1 0.001923 0.001121 endoplasmic reticulum organization BP
GO:0007050 1 0.008278 0.006015 cell cycle arrest BP
GO:0007159 1 0.000706 0.043068 leukocyte cell-cell adhesion BP
GO:0007160 1 9.49E-05 0.000164 cell-matrix adhesion BP
GO:0007162 1 0.000125 0.008967 negative regulation of cell adhesion BP
GO:0007173 1 0.000564 0.016963 epidermal growth factor receptor signaling pathwayBP
GO:0007178 1 5.22E-05 0.000371 transmembrane receptor protein serine/threonine kinase signaling pathwayBP
GO:0007179 1 0.000984 0.011293 transforming growth factor beta receptor signaling pathwayBP
GO:0007249 1 0.007153 0.86915 I-kappaB kinase/NF-kappaB signaling BP
GO:0007250 1 0.001036 0.098349 activation of NF-kappaB-inducing kinase activity BP
GO:0007252 1 0.000374 0.166036 I-kappaB phosphorylation BP
GO:0007265 1 0.005273 0.00077 Ras protein signal transduction BP
GO:0007369 1 0.006329 0.000492 gastrulation BP
GO:0007507 1 0.003736 4.86E-07 heart development BP
GO:0007517 1 1.37E-06 0.013551 muscle organ development BP
GO:0007519 1 9.20E-05 0.491457 skeletal muscle tissue development BP
GO:0007520 1 0.007338 0.362032 myoblast fusion BP
GO:0008064 1 1.63E-05 0.020553 regulation of actin polymerization or depolymerizationBP
GO:0008154 1 0.000234 0.001178 actin polymerization or depolymerization BP
GO:0008361 1 0.005336 0.047538 regulation of cell size BP
GO:0008543 1 3.19E-05 0.138167 fibroblast growth factor receptor signaling pathwayBP
GO:0008625 1 0.007226 0.202811 extrinsic apoptotic signaling pathway via death domain receptorsBP
GO:0008630 1 0.005336 0.000414 intrinsic apoptotic signaling pathway in response to DNA damageBP
GO:0009100 1 2.87E-07 0.033899 glycoprotein metabolic process BP
GO:0009101 1 9.07E-06 0.066893 glycoprotein biosynthetic process BP
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GO:0009225 1 0.004762 0.101281 nucleotide-sugar metabolic process BP
GO:0009226 1 0.00228 0.127075 nucleotide-sugar biosynthetic process BP
GO:0009306 1 0.006959 0.10632 protein secretion BP
GO:0009408 1 0.005577 0.135238 response to heat BP
GO:0009612 1 8.76E-05 3.63E-05 response to mechanical stimulus BP
GO:0010002 1 0.000721 0.142722 cardioblast differentiation BP
GO:0010563 1 5.89E-05 0.000627 negative regulation of phosphorus metabolic processBP
GO:0010631 1 0.004969 3.11E-05 epithelial cell migration BP
GO:0010952 1 0.004521 0.000366 positive regulation of peptidase activity BP
GO:0014706 1 8.37E-05 0.007739 striated muscle tissue development BP
GO:0016050 1 0.001029 0.014164 vesicle organization BP
GO:0016055 1 0.00554 0.077508 Wnt signaling pathway BP
GO:0016197 1 0.002626 0.910158 endosomal transport BP
GO:0016337 1 7.97E-10 2.24E-08 single organismal cell-cell adhesion BP
GO:0016486 1 0.004237 0.032829 peptide hormone processing BP
GO:0016525 1 0.009999 0.073957 negative regulation of angiogenesis BP
GO:0017015 1 0.007793 0.01803 regulation of transforming growth factor beta receptor signaling pathwayBP
GO:0018126 1 0.01 0.12411 protein hydroxylation BP
GO:0018149 1 6.36E-05 0.003178 peptide cross-linking BP
GO:0018196 1 6.14E-06 0.117724 peptidyl-asparagine modification BP
GO:0018208 1 0.005279 0.514836 peptidyl-proline modification BP
GO:0018209 1 0.004846 0.023974 peptidyl-serine modification BP
GO:0018279 1 9.75E-06 0.134584 protein N-linked glycosylation via asparagine BP
GO:0019882 1 0.001576 0.013422 antigen processing and presentation BP
GO:0019884 1 0.000762 0.004572 antigen processing and presentation of exogenous antigenBP
GO:0022406 1 0.002163 0.804615 membrane docking BP
GO:0022408 1 0.003268 0.007736 negative regulation of cell-cell adhesion BP
GO:0022604 1 0.001036 1.73E-07 regulation of cell morphogenesis BP
GO:0022612 1 0.00103 0.000196 gland morphogenesis BP
GO:0022617 1 0.003088 3.32E-06 extracellular matrix disassembly BP
GO:0030036 1 7.07E-09 4.42E-09 actin cytoskeleton organization BP
GO:0030041 1 0.009664 0.032548 actin filament polymerization BP
GO:0030042 1 0.005554 0.1046 actin filament depolymerization BP
GO:0030155 1 0.000122 1.48E-12 regulation of cell adhesion BP
GO:0030166 1 0.005875 0.020936 proteoglycan biosynthetic process BP
GO:0030168 1 0.000274 0.000257 platelet activation BP
GO:0030198 1 3.51E-10 4.19E-22 extracellular matrix organization BP
GO:0030199 1 1.38E-05 0.012168 collagen fibril organization BP
GO:0030203 1 0.006329 0.000847 glycosaminoglycan metabolic process BP
GO:0030204 1 7.63E-05 0.030828 chondroitin sulfate metabolic process BP
GO:0030206 1 0.000766 0.086814 chondroitin sulfate biosynthetic process BP
GO:0030330 1 0.000113 0.047539 DNA damage response, signal transduction by p53 class mediatorBP
GO:0030516 1 4.02E-05 5.90E-05 regulation of axon extension BP
GO:0030517 1 0.006142 0.002332 negative regulation of axon extension BP
GO:0030832 1 1.38E-05 0.021805 regulation of actin filament length BP
GO:0030833 1 0.000195 0.155364 regulation of actin filament polymerization BP
GO:0030838 1 0.00501 0.583753 positive regulation of actin filament polymerizationBP
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GO:0030968 1 8.33E-11 4.06E-05 endoplasmic reticulum unfolded protein responseBP
GO:0031346 1 0.006044 0.000271 positive regulation of cell projection organizationBP
GO:0031349 1 0.001956 0.69149 positive regulation of defense response BP
GO:0031400 1 0.00645 0.013717 negative regulation of protein modification processBP
GO:0031571 1 0.004969 0.17994 mitotic G1 DNA damage checkpoint BP
GO:0031589 1 6.26E-06 1.87E-08 cell-substrate adhesion BP
GO:0031670 1 0.000932 0.011776 cellular response to nutrient BP
GO:0032069 1 1.16E-11 0.000203 regulation of nuclease activity BP
GO:0032075 1 3.02E-12 6.84E-06 positive regulation of nuclease activity BP
GO:0032092 1 0.004174 0.034315 positive regulation of protein binding BP
GO:0032103 1 0.006484 0.125672 positive regulation of response to external stimulusBP
GO:0032319 1 0.009337 0.003882 regulation of Rho GTPase activity BP
GO:0032321 1 0.000252 0.008322 positive regulation of Rho GTPase activity BP
GO:0032535 1 3.52E-07 0.006434 regulation of cellular component size BP
GO:0032612 1 0.005315 0.05584 interleukin-1 production BP
GO:0032635 1 0.001375 0.064587 interleukin-6 production BP
GO:0032637 1 0.00606 0.507663 interleukin-8 production BP
GO:0032652 1 0.001898 0.060206 regulation of interleukin-1 production BP
GO:0032675 1 0.001885 0.052361 regulation of interleukin-6 production BP
GO:0032677 1 0.002146 0.675179 regulation of interleukin-8 production BP
GO:0032732 1 0.001763 0.125048 positive regulation of interleukin-1 production BP
GO:0032943 1 0.001796 0.013621 mononuclear cell proliferation BP
GO:0032946 1 0.000627 0.372415 positive regulation of mononuclear cell proliferationBP
GO:0032956 1 0.000168 0.00323 regulation of actin cytoskeleton organization BP
GO:0032970 1 0.000172 5.60E-05 regulation of actin filament-based process BP
GO:0033209 1 0.00237 0.474224 tumor necrosis factor-mediated signaling pathwayBP
GO:0033673 1 0.005873 0.018038 negative regulation of kinase activity BP
GO:0033674 1 0.000344 1.97E-08 positive regulation of kinase activity BP
GO:0034113 1 0.002401 0.075589 heterotypic cell-cell adhesion BP
GO:0034314 1 0.007507 0.657549 Arp2/3 complex-mediated actin nucleation BP
GO:0034329 1 0.003476 0.00023 cell junction assembly BP
GO:0034330 1 0.002936 4.14E-06 cell junction organization BP
GO:0034349 1 0.000467 0.057203 glial cell apoptotic process BP
GO:0034446 1 0.000105 0.000947 substrate adhesion-dependent cell spreading BP
GO:0034504 1 0.008032 0.008213 protein localization to nucleus BP
GO:0034620 1 5.11E-11 4.26E-05 cellular response to unfolded protein BP
GO:0034976 1 2.44E-11 0.000544 response to endoplasmic reticulum stress BP
GO:0035964 1 0.00594 0.306857 COPI-coated vesicle budding BP
GO:0035966 1 7.05E-10 0.002063 response to topologically incorrect protein BP
GO:0035967 1 5.62E-11 0.000165 cellular response to topologically incorrect proteinBP
GO:0038034 1 0.000868 0.158152 signal transduction in absence of ligand BP
GO:0038093 1 1.17E-06 0.637993 Fc receptor signaling pathway BP
GO:0038094 1 6.36E-06 0.924106 Fc-gamma receptor signaling pathway BP
GO:0038095 1 0.0003 0.26465 Fc-epsilon receptor signaling pathway BP
GO:0038096 1 6.36E-06 0.924106 Fc-gamma receptor signaling pathway involved in phagocytosisBP
GO:0038127 1 0.000128 0.019666 ERBB signaling pathway BP
GO:0038179 1 0.000566 0.212366 neurotrophin signaling pathway BP
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GO:0042098 1 0.001295 0.001354 T cell proliferation BP
GO:0042102 1 0.001893 0.157021 positive regulation of T cell proliferation BP
GO:0042110 1 3.82E-05 0.024723 T cell activation BP
GO:0042326 1 0.000268 0.000348 negative regulation of phosphorylation BP
GO:0042590 1 0.003157 0.41787 antigen processing and presentation of exogenous peptide antigen via MHC class IBP
GO:0042692 1 0.007457 0.007153 muscle cell differentiation BP
GO:0042770 1 0.000202 0.052881 signal transduction in response to DNA damage BP
GO:0043011 1 0.004062 0.529951 myeloid dendritic cell differentiation BP
GO:0043062 1 3.51E-10 4.19E-22 extracellular structure organization BP
GO:0043065 1 0.006764 0.000119 positive regulation of apoptotic process BP
GO:0043068 1 0.00439 9.49E-05 positive regulation of programmed cell death BP
GO:0043122 1 0.009027 0.844844 regulation of I-kappaB kinase/NF-kappaB signalingBP
GO:0043123 1 0.008554 0.809643 positive regulation of I-kappaB kinase/NF-kappaB signalingBP
GO:0043413 1 0.000186 0.402251 macromolecule glycosylation BP
GO:0043516 1 0.001619 0.263843 regulation of DNA damage response, signal transduction by p53 class mediatorBP
GO:0043525 1 0.007721 0.901251 positive regulation of neuron apoptotic process BP
GO:0043542 1 0.003265 3.19E-05 endothelial cell migration BP
GO:0043589 1 0.004212 0.019554 skin morphogenesis BP
GO:0043687 1 0.005717 0.230603 post-translational protein modification BP
GO:0044344 1 0.000113 0.040323 cellular response to fibroblast growth factor stimulusBP
GO:0044783 1 0.006329 0.237627 G1 DNA damage checkpoint BP
GO:0044819 1 0.004137 0.179847 mitotic G1/S transition checkpoint BP
GO:0045103 1 0.006442 0.344566 intermediate filament-based process BP
GO:0045123 1 3.73E-05 0.090706 cellular extravasation BP
GO:0045454 1 0.004632 0.18133 cell redox homeostasis BP
GO:0045773 1 0.000164 0.000274 positive regulation of axon extension BP
GO:0045785 1 0.01 9.46E-10 positive regulation of cell adhesion BP
GO:0045860 1 0.001513 2.84E-08 positive regulation of protein kinase activity BP
GO:0045936 1 5.89E-05 0.000627 negative regulation of phosphate metabolic processBP
GO:0046330 1 0.003326 0.204674 positive regulation of JNK cascade BP
GO:0046651 1 0.002237 0.011998 lymphocyte proliferation BP
GO:0046825 1 0.006852 0.057497 regulation of protein export from nucleus BP
GO:0048002 1 0.000868 0.025681 antigen processing and presentation of peptide antigenBP
GO:0048011 1 0.00036 0.203121 neurotrophin TRK receptor signaling pathway BP
GO:0048193 1 7.22E-10 0.286095 Golgi vesicle transport BP
GO:0048199 1 7.45E-06 0.11361 vesicle targeting, to, from or within Golgi BP
GO:0048200 1 0.00594 0.306857 Golgi transport vesicle coating BP
GO:0048205 1 0.00594 0.306857 COPI coating of Golgi vesicle BP
GO:0048207 1 0.001004 0.138865 vesicle targeting, rough ER to cis-Golgi BP
GO:0048208 1 0.001004 0.138865 COPII vesicle coating BP
GO:0048278 1 0.002074 1 vesicle docking BP
GO:0048514 1 7.17E-07 8.63E-10 blood vessel morphogenesis BP
GO:0048639 1 0.000847 9.20E-05 positive regulation of developmental growth BP
GO:0048675 1 9.11E-05 0.00035 axon extension BP
GO:0048705 1 0.006125 0.034917 skeletal system morphogenesis BP
GO:0048754 1 0.001923 0.000137 branching morphogenesis of an epithelial tube BP
GO:0050650 1 0.001628 0.017497 chondroitin sulfate proteoglycan biosynthetic processBP
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GO:0050654 1 0.00019 0.011739 chondroitin sulfate proteoglycan metabolic processBP
GO:0050663 1 0.001824 0.098837 cytokine secretion BP
GO:0050671 1 0.000863 0.345673 positive regulation of lymphocyte proliferation BP
GO:0050701 1 0.00035 0.084885 interleukin-1 secretion BP
GO:0050704 1 0.000215 0.064776 regulation of interleukin-1 secretion BP
GO:0050707 1 0.001461 0.030183 regulation of cytokine secretion BP
GO:0050708 1 0.007021 0.068069 regulation of protein secretion BP
GO:0050710 1 0.007759 0.118706 negative regulation of cytokine secretion BP
GO:0050716 1 0.003318 0.28321 positive regulation of interleukin-1 secretion BP
GO:0050730 1 0.004705 0.000982 regulation of peptidyl-tyrosine phosphorylation BP
GO:0050732 1 0.002952 0.249107 negative regulation of peptidyl-tyrosine phosphorylationBP
GO:0050772 1 0.003476 4.41E-05 positive regulation of axonogenesis BP
GO:0050852 1 0.006851 0.087974 T cell receptor signaling pathway BP
GO:0050863 1 0.00068 0.423152 regulation of T cell activation BP
GO:0050865 1 0.00947 0.060405 regulation of cell activation BP
GO:0050867 1 0.000548 0.332661 positive regulation of cell activation BP
GO:0050870 1 0.00027 0.359681 positive regulation of T cell activation BP
GO:0050901 1 3.03E-05 0.067848 leukocyte tethering or rolling BP
GO:0051099 1 0.00045 0.02412 positive regulation of binding BP
GO:0051216 1 0.004766 0.000116 cartilage development BP
GO:0051223 1 0.002746 0.002304 regulation of protein transport BP
GO:0051224 1 0.005279 0.053757 negative regulation of protein transport BP
GO:0051249 1 0.000628 0.417826 regulation of lymphocyte activation BP
GO:0051251 1 0.000104 0.421044 positive regulation of lymphocyte activation BP
GO:0051348 1 0.000398 0.040678 negative regulation of transferase activity BP
GO:0051592 1 0.006919 0.00028 response to calcium ion BP
GO:0060326 1 0.004988 0.085416 cell chemotaxis BP
GO:0060348 1 0.003861 0.008574 bone development BP
GO:0060537 1 1.38E-05 0.002257 muscle tissue development BP
GO:0060538 1 0.000118 0.523101 skeletal muscle organ development BP
GO:0060560 1 0.007108 2.40E-05 developmental growth involved in morphogenesisBP
GO:0060561 1 0.004705 0.064652 apoptotic process involved in morphogenesis BP
GO:0061138 1 0.000279 8.72E-07 morphogenesis of a branching epithelium BP
GO:0061387 1 0.004274 6.39E-05 regulation of extent of cell growth BP
GO:0061448 1 0.007356 1.46E-06 connective tissue development BP
GO:0070085 1 6.71E-05 0.407438 glycosylation BP
GO:0070201 1 0.0019 0.000706 regulation of establishment of protein localizationBP
GO:0070527 1 0.005493 0.282279 platelet aggregation BP
GO:0070661 1 0.001226 0.00549 leukocyte proliferation BP
GO:0070663 1 0.005336 0.030169 regulation of leukocyte proliferation BP
GO:0070665 1 0.000566 0.373577 positive regulation of leukocyte proliferation BP
GO:0071158 1 0.002837 0.055893 positive regulation of cell cycle arrest BP
GO:0071260 1 0.000414 0.015974 cellular response to mechanical stimulus BP
GO:0071295 1 0.001098 0.018833 cellular response to vitamin BP
GO:0071496 1 0.000597 0.003561 cellular response to external stimulus BP
GO:0071559 1 0.001264 0.0111 response to transforming growth factor beta BP
GO:0071560 1 0.001264 0.0111 cellular response to transforming growth factor beta stimulusBP
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GO:0071774 1 7.04E-05 0.033579 response to fibroblast growth factor BP
GO:0072012 1 0.006724 0.013925 glomerulus vasculature development BP
GO:0072210 1 0.000414 0.001923 metanephric nephron development BP
GO:0072224 1 0.007739 0.359781 metanephric glomerulus development BP
GO:0072331 1 0.000141 0.011461 signal transduction by p53 class mediator BP
GO:0072384 1 0.001893 0.639679 organelle transport along microtubule BP
GO:0090066 1 6.24E-05 6.86E-05 regulation of anatomical structure size BP
GO:0090092 1 0.003504 0.000428 regulation of transmembrane receptor protein serine/threonine kinase signaling pathwayBP
GO:0090114 1 0.005251 0.075219 COPII-coated vesicle budding BP
GO:0090130 1 0.006329 3.19E-05 tissue migration BP
GO:0090132 1 0.004969 3.11E-05 epithelium migration BP
GO:0090287 1 0.005225 0.003726 regulation of cellular response to growth factor stimulusBP
GO:0097191 1 4.80E-07 0.073232 extrinsic apoptotic signaling pathway BP
GO:0097192 1 0.000868 0.158152 extrinsic apoptotic signaling pathway in absence of ligandBP
GO:0097205 1 0.000164 0.023057 renal filtration BP
GO:0097285 1 0.00113 0.000242 cell-type specific apoptotic process BP
GO:0098602 1 5.11E-11 3.60E-10 single organism cell adhesion BP
GO:1900180 1 0.009399 0.01576 regulation of protein localization to nucleus BP
GO:1902591 1 4.61E-05 0.03292 single-organism membrane budding BP
GO:1902742 1 0.003319 0.024854 apoptotic process involved in development BP
GO:1902807 1 0.003396 0.061689 negative regulation of cell cycle G1/S phase transitionBP
GO:1903034 1 0.009917 0.000533 regulation of response to wounding BP
GO:1990138 1 0.000213 0.000225 neuron projection extension BP
GO:2000134 1 0.003396 0.061689 negative regulation of G1/S transition of mitotic cell cycleBP
GO:2000209 1 0.003839 0.00023 regulation of anoikis BP
GO:2000352 1 0.009071 0.14098 negative regulation of endothelial cell apoptotic processBP
GO:2001233 1 0.007767 0.034613 regulation of apoptotic signaling pathway BP
GO:2001236 1 2.94E-05 0.034603 regulation of extrinsic apoptotic signaling pathwayBP
GO:2001238 1 6.65E-05 0.167836 positive regulation of extrinsic apoptotic signaling pathwayBP
GO:2001239 1 0.000254 0.104853 regulation of extrinsic apoptotic signaling pathway in absence of ligandBP
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